FDA Approved Products

1,302 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Active:Lifecycle: PeakClear all
JORNAY PM
methylphenidate hydrochloride
Peak
ORAL · CAPSULE, EXTENDED RELEASE
Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 yearsolder
2018
NDA
0/100
JUBLIA
efinaconazole
Peak
Bausch + Lomb
TOPICAL · SOLUTION
2014
SMNDA
0/100
JULUCA
dolutegravir sodium and rilpivirine hydrochloride
Peak
GSK
ORAL · TABLET
2017
NDA
0/100
JYLAMVO
methotrexate
Peak
ORAL · SOLUTION
2022
NDA
0/100
KABIVEN IN PLASTIC CONTAINER
dextrose, soybean oil, electrolytes, lysine, phenylalanine, leucine, valine, threonine, methionine, isoleucine, tryptophan, alanine, arginine, glycine, proline, histidine, glutamic acid, serine, aspartic acid and tyrosine
Peak
Fresenius Kabi
INTRAVENOUS · EMULSION
2014
NDA
0/100
KALYDECO
ivacaftor
Peak
Vertex Pharmaceuticals
ORAL · GRANULE
2015
NDA
0/100
KAPSPARGO SPRINKLE
metoprolol succinate
Peak
ORAL · CAPSULE, EXTENDED RELEASE
hypertensionto lower blood pressure+5
2018
NDA
0/100
KATERZIA
amlodipine
Peak
R-Pharm US
ORAL · SUSPENSION
hypertension in adultschildren 6 years+7
2019
SMNDA
0/100
KENGREAL
cangrelor
Peak
Chiesi
INTRAVENOUS · POWDER
2015
NDA
0/100
KEPPRA
levetiracetam
Peak
UCB Pharma
ORAL · TABLET
partial-onset seizures in patients 1 month of ageolder+1
1999
NDA
0/100
KERENDIA
finerenone
Peak
Bayer
ORAL · TABLET
2021
NDA
0/100
KHAPZORY
levoleucovorin
Peak
Acrotech Biopharma
INTRAVENOUS · POWDER
colorectal cancer
2018
NDA
0/100
KIMYRSA
oritavancin diphosphate
Peak
CorMedix
INTRAVENOUS · POWDER
skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptiblemethicillin-resistant isolates)+4
2021
NDA
0/100
KISQALI
ribociclib
Peak
Novartis
ORAL · TABLET
HER2-negative advancedmetastatic breast cancer in combination with: an aromatase inhibitor+4
2017
SMNDA
0/100
KISQALI FEMARA CO-PACK (COPACKAGED)
letrozole and ribociclib
Peak
Novartis
ORAL · TABLET
breast cancer
2017
SMNDA
0/100
KLISYRI
tirbanibulin
Peak
Almirall
TOPICAL · OINTMENT
2020
NDA
0/100
KLOXXADO
naloxone hcl
Peak
Hikma
NASAL · SPRAY
depression
2021
NDA
0/100
KONVOMEP
omeprazole and sodium bicarbonate
Peak
R-Pharm US
ORAL · FOR SUSPENSION
active benign gastric ulcer ( )risk of upper gastrointestinal (GI) bleeding in critically ill patients ( )
2022
NDA
0/100
KORLYM
mifepristone
Peak
Corcept Therapeutics
ORAL · TABLET
2012
NDA
0/100
KRAZATI
adagrasib
Peak
Bristol Myers Squibb
ORAL · TABLET
metastatic non-small cell lung cancer (NSCLC)metastatic colorectal cancer (CRC)+4
2022
NDA
0/100
KUVAN
sapropterin dihydrochloride
Peak
BioMarin Pharmaceutical
ORAL · POWDER
blood phenylalanine (Phe) levels in adultolder with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin‑ (BH4‑) responsive Phenylketonuria (PKU)
2013
NDA
0/100
KYBELLA
deoxycholic acid
Peak
AbbVie
SUBCUTANEOUS · SOLUTION
2015
NDA
0/100
KYNMOBI
apomorphine hydrochloride
Peak
Sumitomo Dainippon Pharma
SUBLINGUAL · FILM
2020
NDA
0/100
KYPROLIS
carfilzomib
Peak
INTRAVENOUS · POWDER
2012
NDA
0/100